Kristie L. Kahl

Join the 43rd Annual Chemotherapy Foundation Symposium in New York City for cutting-edge cancer care education and networking opportunities.

Nivolumab plus ipilimumab shows significant progression-free survival benefits in metastatic colorectal cancer, establishing a new standard of care.

Combination therapy with sacituzumab govitecan and pembrolizumab enhances quality of life and delays physical decline in metastatic triple-negative breast cancer patients.

The OPTIC RCC trial reveals promising outcomes for patients with angiogenic tumors treated with cabozantinib and nivolumab, showcasing high response rates and tumor reduction.

Sacituzumab govitecan significantly improves progression-free survival in advanced triple-negative breast cancer, offering a promising alternative to chemotherapy.

Gedatolisib enhances progression-free survival in advanced breast cancer patients, showcasing significant benefits when combined with fulvestrant and palbociclib.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.

David A. Braun, MD, PhD, reveals how integrating tumor and circulating biomarkers enhances treatment response predictions in advanced renal cell carcinoma.

Sevabertinib demonstrated high and durable objective response rates in pretreated and treatment-naive HER2-mutant NSCLC, with a manageable safety profile.

Fruquintinib plus camrelizumab, paclitaxel liposome, and nedaplatin showed a 68.4% ORR and acceptable safety in advanced ESCC.

Aspirin reduced recurrence risk by 50% in PIK3CA-mutated colorectal cancer, per 3-year ALASCCA trial results.

Primary results from the phase 3 AQUILA study showed that subcutaneous daratumumab elicited a significant improvement in PFS compared with active monitoring in patients with smoldering multiple myeloma.

The all-oral, fixed-duration, frontline regimen of acalabrutinib plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival vs standard chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Among patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, MRD-negativity rates and progression-free survival were improved with daratumumab plus VRd versus VRd alone.

Updated results from the phase 2 AUGMENT-101 trial showed that revumenib continued to provide clinically meaningful responses in patients with relapsed or refractory acute leukemia with a KMT2Ar translocation.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed on or after amivantamab.

Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and thymic carcinoma.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Retrospective data from the International Metastatic Renal Cell Carcinoma Database Consortium showed limited response rates in patients treated with tyrosine kinase inhibitors who received prior lenvatinib.

Tucidinostat plus R-CHOP demonstrated promising safety and efficacy outcomes in patients with previously untreated diffuse large B-cell lymphoma) expressing MYC and BCL-2.

Adagrasib significantly improved responses among patients with KRASG12C-mutated locally advanced or metastatic non–small cell lung cancer.

A higher dose of radiation therapy led to longer progression-free, cancer-specific, and overall survival, compared with the standard dose, in combination with long-term ADT in patients with high-risk prostate cancer.

The frontline use of pembrolizumab plus lenvatinib in patients with advanced HCC showed a 3-year or more response among 35% of responders; however, additional efficacy results remained consistent with previous findings from the phase 3 LEAP-002 trial.

Study findings support the use of a financial navigation program, in hopes to aid patients with multiple myeloma affected by financial toxicity.

Treatment with zanubrutinib, obinutuzumab, and venetoclax, also known as BOVen, showed promising safety and efficacy in treatment-naive patients with TP53-mutant mantle cell lymphoma.

Acalabrutinib-containing regimens continued to improve progression-free survival, especially when a complete response is obtained, compared with obinutuzumab plus chlorambucil, in treatment-naive patients with chronic lymphocytic leukemia, according to a 6-year follow-up.

In the final analysis of the phase 2 ELM-2 trial, odronextamab monotherapy showed encouraging efficacy, with a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma.

According to extended follow-up of the phase 3 ALPINE trial, treatment with zanubrutinib continued to demonstrate improved progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.